Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

BACKGROUND: Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) will relapse if treatment is withdrawn, but various trials have recently demonstrated that a significant proportion of patients who achieved a stable and deep molecular response (DMR) can sto...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerveira, Nuno, Loureiro, Bruno, Bizarro, Susana, Correia, Cecília, Torres, Lurdes, Lisboa, Susana, Vieira, Joana, Santos, Rui, Pereira, Dulcineia, Moreira, Cláudia, Chacim, Sérgio, Domingues, Nélson, Espírito-Santo, Ana, Oliveira, Isabel, Moreira, Ilídia, Viterbo, Luísa, Martins, Ângelo, Teixeira, Manuel R., Mariz, José M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292043/
https://www.ncbi.nlm.nih.gov/pubmed/30541488
http://dx.doi.org/10.1186/s12885-018-5167-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292043/
https://www.ncbi.nlm.nih.gov/pubmed/30541488
http://dx.doi.org/10.1186/s12885-018-5167-y

Ejemplares similares